Cargando...
Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer
The introduction of trastuzumab into clinical practice changed the natural course of HER2-positive breast cancer. Currently, treatment with trastuzumab represents the standard of care for HER2-positive breast cancer and this treatment has been approved in the adjuvant, neoadjuvant, and metastatic se...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2013
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4123423/ https://ncbi.nlm.nih.gov/pubmed/23377763 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12282-013-0446-6 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|